DXP
Disease Modifying Therapy
Friday, June 1, 2018: 2:00 PM-4:00 PM
209 (Nashville Music City Center)
2:00 PM
Confirmed Disability Improvement in Patients with Relapsing Multiple Sclerosis in the Open-Label Extension Period of the Pooled Opera Trials
Robert T Naismith, MD, Washington University School of Medicine;
Stephen L Hauser, MD, University of California;
Bruno Brochet, MD, University of Bordeaux;
Xavier Montalban, MD, PhD, Vall d’Hebron University Hospital;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Laura Julian, PhD, Genentech, Inc.;
Pablo Villoslada, MD, Genentech, Inc.;
Fabian Model, PhD, F. Hoffmann-La Roche Ltd;
Stanislas Hubeaux, MSc, F. Hoffmann-La Roche Ltd;
Ludwig Kappos, MD, University of Basel
2:17 PM
Durable Improvements in MRI Disease Activity and Brain Volume Loss with Alemtuzumab in RRMS Patients: 7-Year Follow-up of Care-MS II
Daniel Pelletier, MD, Keck School of Medicine of University of Southern California;
Anthony Traboulsee, MD, University of British Columbia;
Michael Barnett, PhD, MD, University of Sydney;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Jerome de Seze, MD PhD, University Hospital of Strasbourg;
Alex Rovira, MD, Vall d'Hebron University Hospital;
Sven Schippling, MD, Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich and University of Zurich;
Luke Chung, MD, MPH, Sanofi;
Nadia Daizadeh, PhD, Sanofi;
Kunio Nakamura, PhD, Cleveland Clinic;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University;
on behalf of the CARE-MS II, CAMMS03409, and TOPAZ, Investigators, on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators
2:34 PM
Active RRMS Patients Show Disability Improvements in Each Functional System Following Treatment with Alemtuzumab: Results from Care-MS II Extension
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute;
Rany A Aburashed, DO, Institute for Neurosciences and Multiple Sclerosis;
Raed Alroughani, MD, Amiri Hospital;
Steven M Bromley, MD, FAAN, South Jersey MS Center;
Dominique Dive, MD, PhD, University Hospital Centre of Liege;
Guillermo Izquierdo, MD, Virgen Macarena University Hospital;
Ho Jin Kim, MD, Research Institute and Hospital of National Cancer Center;
Jan Lycke, MD, Sahlgrenska University Hospital;
Richard AL Macdonell, MD, Austin Health and Florey Institute of Neuroscience and Mental Health;
Carlo Pozzilli, MD, Sapienza University of Rome;
Basil Sharrack, MD, PhD, Sheffield Teaching Hospitals NHS Foundation Trust;
Patrick Vermersch, MD, University of Lille;
Andreas Lysandropoulos, MD, PhD, Sanofi;
Luke Chung, MD, MPH, Sanofi;
Nadia Daizadeh, PhD, Sanofi;
Heinz Wiendl, MD, University of Munster;
on behalf of the CARE-MS II and CAMMS03409, Investigators, on behalf of the CARE-MS II and CAMMS03409 Investigators
2:51 PM
Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Developing Progressive Disease
Ralph H Benedict, PhD, University at Buffalo;
Jerome de Seze, MD, PhD, University Hospital of Strasbourg;
Stephen L Hauser, MD, University of California, San Francisco;
Ludwig Kappos, MD, University Hospital Basel, University of Basel;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Hanzhe Zheng, PhD, Genentech, Inc.;
Shibeshih Belachew, MD, PhD, F. Hoffmann-La Roche Ltd;
Laura Julian, PhD, Genentech, Inc.;
Ashish Pradhan, MD, Genentech, Inc.;
Fred Lublin, MD, Icahn School of Medicine at Mount Sinai;
Stanley Cohan, MD, PhD, Providence Multiple Sclerosis Center
3:08 PM
Effects of Fingolimod on Magnetic Resonance Imaging Outcomes in Patients with Pediatric-Onset Multiple Sclerosis: Results from the Phase 3 Paradigms Study
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University;
Brenda Banwell, MD, Children's Hospital of Philadelphia;
Amit Bar-Or, MD, Neuroimmunology Unit, Montreal Neurological Institute and Hospital;
Angelo Ghezzi, MD, Gallarate Hospital;
Benjamin Greenberg, MD, MHS, UT Southwestern Medical Center;
Emmanuelle Waubant, MD, PhD, Weill Institute for Neurosciences;
Gavin Giovannoni, PhD, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Jutta Gaertner, MD, Department of Paediatrics and Adolescent Medicine, German Centre for Multiple Sclerosis in Childhood and Adolescence University Medical Centre;
Kevin Rostasy, MD, Division of Paediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke;
Lauren Krupp, MD, Pediatric MS Center, NYU Langone Medical Center;
Marc Tardieu, MD, Bicetre Hospital;
Wolfgang Brueck, MD, Department of Neuropathology, University Medical Centre;
Tracy Stites, PhD, Novartis Pharmaceuticals Corporation;
Gregory L Pearce, PhD, Novartis Pharmaceuticals Corporation;
Martin Merschhemke, MD, PhD, Novartis Pharma AG;
Tanuja Chitnis, MD, Partners Pediatric MS Center
3:25 PM
Efficacy and Safety of Ozanimod Versus Interferon Beta 1A
Bruce AC Cree, MD, PhD, Weill Institute for Neurosciences;
Amit Bar-Or, MD, Center for Neuroinflammation and Therapeutics, and Multiple Sclerosis Division, University of Pennsylvania;
Giancarlo Comi, MD, San Raffaele Scientific Institute, Vita-Salute San Raffaele University;
Krzysztof W Selmaj, MD, PhD, Medical University of Lodz;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University;
Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center;
Hans-Peter Hartung, MD, Heinrich-Heine University;
Xavier Montalban, MD, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d’Hebron;
Eva K Havrdova, MD, PhD, Charles University;
James K Sheffield, MD, Receptos, a wholly owned subsidiary of Celgene;
Kartik Raghupathi, PhD, Receptos, a wholly owned subsidiary of Celgene;
Ludwig Kappos, MD, University of Basel;
Jeffrey A Cohen, MD, Cleveland Clinic
3:42 PM
Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants;
Amy Lovett-Racke, PhD, Ohio State University Medical Center;
Matilde Inglese, MD, PhD, Mount Sinai School of Medicine;
Maria Petracca, MD, PhD, Icahn School of Medicine at Mount Sinai;
Sibyl Wray, MD, Hope Neurology MS Center;
Michael K Racke, MD, Wexner Medical Center, Ohio State University;
Richard Shubin, MD, SC3 Research Group, Inc;
Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA;
Michael Weiss, JD, TG Therapeutics, Inc;
James Eubanks, PhD, TG Therapeutics, Inc;
Koby Mok, PhD, TG Therapeutics, Inc;
Wendy Su, PhD, TG Therapeutics, Inc
